Steris Plc (STE) - Q1 Fiscal 2027 Summary
Business Context and Reporting Period
This summary covers the unaudited quarterly results for Steris Plc for the three months ended June 30, 2026 (First Quarter of Fiscal 2027). Steris is a global provider of products and services supporting patient care, with a focus on infection prevention. The company operates through three reportable segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences.
Key Financial Metrics
| Metric (in millions, except per share) | Q1 2027 (Ended June 30, 2026) | Q1 2026 (Ended June 30, 2025) |
|---|---|---|
| Total Revenues | $1,492.7 | $1,391.1 |
| Gross Profit | $684.2 | $628.0 |
| Gross Margin | 45.8% | 45.1% |
| Income from Operations | $285.8 | $246.0 |
| Net Income (Attributable to Shareholders) | $200.1 | $177.4 |
| Diluted EPS | $2.04 | $1.79 |
| Operating Cash Flow | $367.1 | $420.0 |
| Free Cash Flow | $279.6 | $326.5 |
| Total Debt | $1,893.7 | $1,931.7 |
| Cash and Equivalents | $482.3 | $279.7 |
| Debt-to-Total Capital Ratio | 20.9% | 21.5% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 7.3% year-over-year, driven by higher volume in Healthcare and Life Sciences segments and pricing across all segments. Service revenues grew 7.8%, consumables 9.0%, and capital equipment 3.0%.
- Profitability: Operating income rose 16.2% to $285.8 million. Gross margin expanded 70 basis points to 45.8%, aided by pricing, productivity, and mix, partially offset by inflation.
- Segment Performance:
- Healthcare: Revenues up 7.6% to $1,048.3 million; operating income up 10.5% to $260.2 million.
- AST: Revenues up 5.8% to $297.6 million; operating income up 4.6% to $142.9 million.
- Life Sciences: Revenues up 8.6% to $146.7 million; operating income up 5.1% to $61.8 million.
- Restructuring: No restructuring expenses were incurred in Q1 2027, compared to $1.8 million in Q1 2026. The prior restructuring plan is substantially complete.
- Cash Flow: Operating cash flow decreased to $367.1 million (from $420.0 million) due to a lower contribution from working capital, despite higher net income.
Guidance, Outlook, and Risks
- New Restructuring Plan: On August 5, 2026, management announced a new targeted restructuring plan to consolidate chemistry manufacturing and distribution to a new Center of Excellence in North Carolina. The company expects to incur total pre-tax charges of $55 million to $70 million over time, with completion anticipated by fiscal 2030. No financial impact has been recognized to date.
- Share Repurchases: The Board authorized a new $1.0 billion share repurchase program in May 2026. During Q1 2027, the company repurchased $100.0 million of shares, leaving $900.0 million of remaining availability.
- Dividends: Cash dividends declared were $0.63 per share, an increase from $0.57 in the prior year.
- Legal Contingencies:
- Illinois EO Litigation: The company settled claims related to ethylene oxide emissions for up to $48.2 million. As of July 31, 2026, substantially all payment obligations were satisfied.
- IRS Dispute: The company is contesting IRS Notices of Deficiency regarding a deemed dividend matter from fiscal 2018, which could result in a cumulative tax liability of approximately $50.0 million if assessed. No reserves have been established.
- Tax Legislation: The "One Big Beautiful Bill Act" (OBBBA) signed in July 2025 did not materially impact Q1 2027 results, though future impacts remain uncertain.
Investor Verification Checklist
- Restructuring Costs: Verify the timing and cash impact of the new $55M-$70M restructuring plan announced in August 2026.
- Working Capital Trends: Investigate the reasons for the significant decrease in operating cash flow contribution from working capital compared to the prior year.
- IRS Litigation: Monitor the status of the U.S. Tax Court petitions regarding the $50 million potential tax liability.
- Share Buyback Execution: Track the pace of the new $1.0 billion repurchase program and its impact on share count.
- Backlog Levels: Review the Healthcare segment backlog ($444.0 million) and Life Sciences backlog ($109.9 million) for future revenue visibility.